No Data
No Data
News On Karuna Therapeutics Inc. (KRTX) Now Under BMY
News On Karuna Therapeutics Inc. (KRTX) Now Under BMY
Bristol Myers Squibb Completes Acquisition Of PureTech's Founded Entity Karuna Therapeutics For $14 Billion PRTC.LN
Bristol Myers Squibb Completes Acquisition Of PureTech's Founded Entity Karuna Therapeutics For $14 Billion PRTC.LN
Karuna Therapeutics Undergoes Extensive Corporate Transformation
Press Release: Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio KarXT, Karuna's Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Mult
When Will Karuna Therapeutics, Inc. (NASDAQ:KRTX) Become Profitable?
We feel now is a pretty good time to analyse Karuna Therapeutics, Inc.'s (NASDAQ:KRTX) business as it appears the company may be on the cusp of a considerable accomplishment. Karuna Therapeutics, In
Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term
No Data